Skip to content
DataLookout
Menu

NCT07582120

Psilocybin-Assisted Therapy as a Treatment for Depression

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 3 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 6 more changesShow less
    • Start date changed from estimate of Jun 2026 to Nov 1, 2026
    • Eligibility criteria expanded, about 22 words
    • Primary completion date: Jun 2031 to Jun 15, 2031
    • Study completion date: Dec 2031 to Dec 15, 2031
    • Site details revised
    • Publications: details revised at 1 of 1 entry
  2. Minor Study sites: 0 to 1v3
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Characterize ACUTE (~1 week post-dose) and PERSISTING (~30 days post-dose) effects of PAT in depressed adults at two possible administrations on depression symptom severity using the Montgomery-Asberg Depression Rating Scale (MADRS) score.
Timeframe: 1 week and 30 days post-dose for both administration sessions
Characterize ACUTE (~1 week post-dose) and PERSISTING (~30 days post-dose) effects of PAT in depressed adults at two possible administrations on psychological flexibility using the Multidimensional Psychological Flexibility Inventory (MPFI).
Timeframe: 1 week and 30 days post-dose for both administration sessions

Arms and interventions

25mg Open Label dose of synthetic psilocybinExperimental

Drugs: Psilocybin (Usona Institute)

Sites

1 site in 1 country

  • Washington University School of MedicineSt Louis, Missouri, United States